Drugs / fluticasone proprionate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT03141424 | Jun 2022 → Oct 2024 | asthma | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00867737 | Sep 2008 → Sep 2009 | asthma | Allergy and Asthma Center of El Paso | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT03376932 Comparator | Jan 2019 → Feb 2021 | asthma | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 4 | NCT01246921 Comparator | Sep 2009 → Aug 2011 | vitiligo | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-05-19 | GlaxoSmithKline | Results GSK presents positive data at ATS 2014 from study evaluating efficacy and safety of Incruse™ Ellipta® added to Advair® Diskus® in patients with COPD gsk.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-05-19 | GlaxoSmithKline | GSK presents positive data at ATS 2014 from study evaluating efficacy and safety of Incruse™ Ellipta® added to Advair® Diskus® in patients with COPD gsk.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fluticasone proprionate | “Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol...” NCT03376932 ↗3“Advair = fluticasone proprionate plus salmeterol” NCT00867737 ↗ “fluticasone proprionate” NCT03141424 ↗ |
| Modality | Other / unclassified | “inhaled corticosteroid (ICS) treatment” NCT03141424 ↗ |
| Route | Inhaled | “Two puffs from MDI twice daily for 4 weeks” NCT00867737 ↗ |